Bottom line
RSPH vs LOGSX: the short answer
RSPH (Invesco S&P 500 Equal Weight Health Care ETF) and LOGSX (Live Oak Health Sciences Fund) are quite different portfolios: only about 21% of their top holdings (by weight) are shared.
But RSPH is far broader, holding 63 positions to 28 for LOGSX, so beyond the top names it adds exposure LOGSX doesn't have.
RSPH is cheaper at 0.4% vs 1.04% — a difference of $64 a year per $10,000 invested.
Over five years, LOGSX returned +8.1% a year vs +4.7% for RSPH.
Updated Nov 19, 2026
RSPH vs LOGSX side by side
| RSPH | LOGSX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | Invesco | Oak Associates |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.4% | 1.04% |
| Annual cost per $10k | $40 | $104 |
| 10-yr cost on $10k (prospectus) | $505 | $1,271 |
| Max front load | None | — |
| 12b-1 fee | — | — |
| 1-yr return | +9.3% | +19.6% |
| 5-yr return (annualized) | +4.7% | +8.1% |
| 10-yr return (annualized) | +8.2% | +7.3% |
| Best quarter | +17.5% | +13.4% |
| Worst quarter | −14.3% | −13.1% |
| Net assets (fund) | $766.9M | $56.1M |
| Number of holdings | 63 | 28 |
| Portfolio turnover | 24% | 24% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | RSPH | LOGSX | Difference |
|---|---|---|---|
| 2025 | +9.3% | +19.6% | −10.3% |
| 2024 | −0.8% | +0.2% | −1.0% |
| 2023 | +3.9% | +1.2% | +2.7% |
| 2022 | −9.2% | +3.7% | −13.0% |
| 2021 | +23.0% | +17.5% | +5.5% |
| 2020 | +18.9% | +6.0% | +12.9% |
| 2019 | +25.3% | +19.0% | +6.4% |
| 2018 | −0.3% | −4.0% | +3.6% |
| 2017 | +23.4% | +13.4% | +10.0% |
| 2016 | −4.5% | −0.4% | −4.1% |
Source: Fund prospectus bar charts
Holdings overlap
6 of RSPH's top 25 holdings also appear in LOGSX's top 25.
| Holding | RSPH | LOGSX |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 1.96% | 4.43% |
| Bristol-Myers Squibb Co. | 1.82% | 4.02% |
| Labcorp Holdings Inc. | 1.78% | 2.29% |
| Amgen Inc. | 1.77% | 4.86% |
| Incyte Corp. | 1.76% | 3.30% |
| Cencora, Inc. | 1.71% | 4.46% |
Source: SEC Form N-PORT
RSPH top 10
- Bio-Techne Corp. — 2.13%
- IQVIA Holdings Inc. — 2.00%
- Baxter International Inc. — 1.99%
- Regeneron Pharmaceuticals, Inc. — 1.96%
- Mettler-Toledo International Inc. — 1.94%
- Charles River Laboratories International, Inc. — 1.93%
- Veeva Systems Inc. — 1.93%
- DaVita Inc. — 1.87%
- Moderna, Inc. — 1.85%
- Thermo Fisher Scientific Inc. — 1.84%
LOGSX top 10
- N/a — 6.91%
- Cardinal Health Inc — 5.86%
- Jazz Pharmaceuticals Plc — 5.77%
- United Therapeutics Corp — 5.11%
- Exelixis Inc — 4.95%
- Amgen Inc — 4.86%
- Lantheus Holdings Inc — 4.68%
- Novartis Ag — 4.67%
- Mckesson Corp — 4.53%
- Cencora Inc — 4.46%
FAQ
What is the difference between RSPH and LOGSX?
Which is cheaper, RSPH or LOGSX?
Should I own both RSPH and LOGSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.